715 related articles for article (PubMed ID: 36765684)
21. Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect.
Liu Z; Zhang Y; Shen N; Sun J; Tang Z; Chen X
Adv Drug Deliv Rev; 2022 Apr; 183():114138. PubMed ID: 35143895
[TBL] [Abstract][Full Text] [Related]
22. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.
Ahmad RS; Eubank TD; Lukomski S; Boone BA
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204306
[TBL] [Abstract][Full Text] [Related]
23. Deciphering the role of stroma in pancreatic cancer.
Waghray M; Yalamanchili M; di Magliano MP; Simeone DM
Curr Opin Gastroenterol; 2013 Sep; 29(5):537-43. PubMed ID: 23892539
[TBL] [Abstract][Full Text] [Related]
24. High-resolution 3D visualization of nanomedicine distribution in tumors.
Moss JI; Barjat H; Emmas SA; Strittmatter N; Maynard J; Goodwin RJA; Storm G; Lammers T; Puri S; Ashford MB; Barry ST
Theranostics; 2020; 10(2):880-897. PubMed ID: 31903157
[TBL] [Abstract][Full Text] [Related]
25. Exploring the tumor microenvironment with nanoparticles.
Miao L; Huang L
Cancer Treat Res; 2015; 166():193-226. PubMed ID: 25895870
[TBL] [Abstract][Full Text] [Related]
26. An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer.
Ji T; Li S; Zhang Y; Lang J; Ding Y; Zhao X; Zhao R; Li Y; Shi J; Hao J; Zhao Y; Nie G
ACS Appl Mater Interfaces; 2016 Feb; 8(5):3438-45. PubMed ID: 26759926
[TBL] [Abstract][Full Text] [Related]
27. Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.
Wang X; Li S; Liu X; Wu X; Ye N; Yang X; Li Z
Adv Exp Med Biol; 2021; 1295():77-95. PubMed ID: 33543456
[TBL] [Abstract][Full Text] [Related]
28. The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies.
Perez VM; Kearney JF; Yeh JJ
Front Oncol; 2021; 11():751311. PubMed ID: 34692532
[TBL] [Abstract][Full Text] [Related]
29. Antifibrotic therapy to normalize the tumor microenvironment.
Hauge A; Rofstad EK
J Transl Med; 2020 May; 18(1):207. PubMed ID: 32434573
[TBL] [Abstract][Full Text] [Related]
30. From Passive Targeting to Personalized Nanomedicine: Multidimensional Insights on Nanoparticles' Interaction with the Tumor Microenvironment.
Sebak AA; El-Shenawy BM; El-Safy S; El-Shazly M
Curr Pharm Biotechnol; 2021; 22(11):1444-1465. PubMed ID: 33308126
[TBL] [Abstract][Full Text] [Related]
31. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells.
Lee HO; Mullins SR; Franco-Barraza J; Valianou M; Cukierman E; Cheng JD
BMC Cancer; 2011 Jun; 11():245. PubMed ID: 21668992
[TBL] [Abstract][Full Text] [Related]
32. Pathophysiological role of microRNA-29 in pancreatic cancer stroma.
Kwon JJ; Nabinger SC; Vega Z; Sahu SS; Alluri RK; Abdul-Sater Z; Yu Z; Gore J; Nalepa G; Saxena R; Korc M; Kota J
Sci Rep; 2015 Jun; 5():11450. PubMed ID: 26095125
[TBL] [Abstract][Full Text] [Related]
33. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
Shi Y; van der Meel R; Chen X; Lammers T
Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
[TBL] [Abstract][Full Text] [Related]
34. Thermosensitive Liposomal Codelivery of HSA-Paclitaxel and HSA-Ellagic Acid Complexes for Enhanced Drug Perfusion and Efficacy Against Pancreatic Cancer.
Wei Y; Wang Y; Xia D; Guo S; Wang F; Zhang X; Gan Y
ACS Appl Mater Interfaces; 2017 Aug; 9(30):25138-25151. PubMed ID: 28696100
[TBL] [Abstract][Full Text] [Related]
35. Effects of tumor microenvironments on targeted delivery of glycol chitosan nanoparticles.
Yhee JY; Jeon S; Yoon HY; Shim MK; Ko H; Min J; Na JH; Chang H; Han H; Kim JH; Suh M; Lee H; Park JH; Kim K; Kwon IC
J Control Release; 2017 Dec; 267():223-231. PubMed ID: 28917532
[TBL] [Abstract][Full Text] [Related]
36. Cyclopamine treatment disrupts extracellular matrix and alleviates solid stress to improve nanomedicine delivery for pancreatic cancer.
Zhang B; Wang H; Jiang T; Jin K; Luo Z; Shi W; Mei H; Wang H; Hu Y; Pang Z; Jiang X
J Drug Target; 2018 Dec; 26(10):913-919. PubMed ID: 29533111
[TBL] [Abstract][Full Text] [Related]
37. Modulating the tumor microenvironment with new therapeutic nanoparticles: A promising paradigm for tumor treatment.
Zhang Y; Ho SH; Li B; Nie G; Li S
Med Res Rev; 2020 May; 40(3):1084-1102. PubMed ID: 31709590
[TBL] [Abstract][Full Text] [Related]
38. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship.
Weniger M; Honselmann KC; Liss AS
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30200666
[TBL] [Abstract][Full Text] [Related]
39. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
[TBL] [Abstract][Full Text] [Related]
40. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
